Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Clinical Nuclear Medicine|May 1, 1990
Pleuroperitoneal communication associated with malignant ascites. A potential cause for new pleural effusion suggestive of pulmonary embolismA F Jacobson, M D Cerqueira, H B Breitz, et al.Cancer Biotherapy & Radiopharmaceuticals|June 13, 2000
Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidinH B Breitz, D R Fisher, M L Goris, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 1, 1995
Pharmacokinetics and normal organ dosimetry following intraperitoneal rhenium-186-labeled monoclonal antibodyH B Breitz, J S Durham, D R Fisher, et al.Cancer Biotherapy & Radiopharmaceuticals|March 31, 2000
Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study resultsP L Weiden, H B Breitz, O Press, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 27, 2000
Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotinH B Breitz, P L Weiden, P L Beaumier, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 1, 1993
Dosimetry of rhenium-186-labeled monoclonal antibodies: methods, prediction from technetium-99m-labeled antibodies and results of phase I trialsH B Breitz, D R Fisher, P L Weiden, et al.Cancer|February 1, 1994
Human anti-mouse antibody suppression with cyclosporin AP L Weiden, S B Wolf, H B Breitz, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 1, 1993
Rhenium-186-labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10P L Weiden, H B Breitz, C A Seiler, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 1, 1992
Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trialsH B Breitz, P L Weiden, J L Vanderheyden, et al.Pageof 2